NEW YORK (GenomeWeb News) – Qiagen and Lilly inked their third companion diagnostic deal this week.

The companies did not disclose the drug or the molecular diagnostic target that the test will gauge.

Qiagen highlighted that the latest deal "builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.